- Home
- CNTX vs WHWK Comparison
CNTX vs WHWK Comparison
Compare CNTX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- WHWK
- Stock Information
- Founded
- CNTX 2015
- WHWK 2007
- Country
- CNTX United States
- WHWK United States
- Employees
- CNTX N/A
- WHWK N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- WHWK Health Care
- Exchange
- CNTX Nasdaq
- WHWK Nasdaq
- Market Cap
- CNTX 75.6M
- WHWK 90.0M
- IPO Year
- CNTX 2021
- WHWK N/A
- Fundamental
- Price
- CNTX $1.13
- WHWK $2.19
- Analyst Decision
- CNTX Strong Buy
- WHWK
- Analyst Count
- CNTX 7
- WHWK 0
- Target Price
- CNTX $5.20
- WHWK N/A
- AVG Volume (30 Days)
- CNTX 260.4K
- WHWK 133.0K
- Earning Date
- CNTX 11-05-2025
- WHWK 11-15-2025
- Dividend Yield
- CNTX N/A
- WHWK N/A
- EPS Growth
- CNTX N/A
- WHWK N/A
- EPS
- CNTX N/A
- WHWK N/A
- Revenue
- CNTX N/A
- WHWK $21,596,000.00
- Revenue This Year
- CNTX N/A
- WHWK N/A
- Revenue Next Year
- CNTX N/A
- WHWK N/A
- P/E Ratio
- CNTX N/A
- WHWK N/A
- Revenue Growth
- CNTX N/A
- WHWK N/A
- 52 Week Low
- CNTX $0.49
- WHWK $1.39
- 52 Week High
- CNTX $2.59
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- CNTX 69.12
- WHWK 78.67
- Support Level
- CNTX $0.98
- WHWK $1.85
- Resistance Level
- CNTX $1.29
- WHWK $1.97
- Average True Range (ATR)
- CNTX 0.09
- WHWK 0.10
- MACD
- CNTX 0.02
- WHWK 0.03
- Stochastic Oscillator
- CNTX 65.91
- WHWK 88.64
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.